Date of Last Revision

2023-05-02 21:46:49



Degree Name

Bachelor of Science

Date of Expected Graduation

Fall 2016


Preeclampsia is a disease that results in pathologies in both the mother and the fetus that lead to oxidative stress. A decrease in vascular endothelial growth factor (VEGF) signaling may be one factor that contributes to this pathology. We hypothesize that by increasing vascular endothelial growth factor receptor 2 (VEGFR2) expression via administration of L-tyrosine phosphate (LTP) nanoparticles, the conditions of both the mother and fetus will be improved. Following treatment with the nanoparticles, we will employ a lucigenin chemiluminescence assay to determine levels of oxidative stress within the placenta. There are three groups that will be compared which are the control group and two experimental groups. The control group is the SHAM, one experimental group is the reduced uterine perfusion pressure (RUPP), a common model for preeclampsia, and the other experimental group is the RUPP treated with the nanoparticle. Once finished, we hypothesize that placental samples from VEGFR2-treated RUPP animals will display less oxidative stress than untreated RUPP animals, similar to that seen from SHAM controls. These studies will indicate whether RUPP pathology is associated with placental oxidative stress, and identify potential therapeutic roles for VEGFR2 nanoparticles.

Research Sponsor

Rolando J. Ramirez

First Reader

Leah Shriver

Second Reader

Jordan M. Renna

Included in

Biology Commons



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.